Format

Send to

Choose Destination
Trends Biotechnol. 2017 Nov;35(11):1062-1073. doi: 10.1016/j.tibtech.2017.07.004. Epub 2017 Aug 1.

The Business of Anti-Aging Science.

Author information

1
Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK; Joint first authors. Electronic address: jp@senescence.info.
2
Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK; Joint first authors.
3
Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L7 8TX, UK.

Abstract

Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.

KEYWORDS:

Big Pharma; biogerontology; geroscience; longevity; pharmacology; translational research

PMID:
28778607
DOI:
10.1016/j.tibtech.2017.07.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center